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Antibiotic resistance has been referred to as “the silent
tsunami facing modern medicine” [1]. It has been the
topic of numerous international health summits and
political summits. An abundance of comprehensive re-
ports, guidelines and recommendations both on an inter-
national and on a national level have been published to
tackle the threats posed by antibiotic resistance. Despite
this awareness in science and politics and the more re-
cent attention by mass media, antibiotic resistance con-
tinues to increase throughout the world.
In this context, the rise of multidrug resistance in Gram-
negative bacteria (MDR-GNB) has become a particularly
serious challenge for healthcare professionals. During a
two-day symposium held by Rudolf-Schülke-Stiftung,
Hamburg, an expert panel of renowned infection preven-
tionists from Germany, Austria, India and the U.S. dis-
cussed current perspectives with regard to prevention of
emergence and spread of multidrug-resistant Gram-neg-
ative bacteria (MDR-GNB). The consensus report below
outlines key elements of a One Health approach, taking
into considerations various aspects such as special fea-
tures of Gram-negative bacteria and their antibiotic resist-
ance, the epidemiological situation worldwide, reservoirs,
transmission paths, risk groups, treatment options, and
effectiveness of existing prevention strategies.
2Main properties of Gram-negative
bacteria and multidrug resistance
in Gram-negative bacteria
Gram-negative bacteria (GNB) differ from Gram-positive
bacteria with respect to the structure of the cell wall. This
results in differences in the penetration and retention of
chemical agents. Gram-negative bacteria have what is
referred to as envelope, consisting of three principal lay-
ers:
1. the outer membrane, containing the (possibly fatal)
lipopolysaccharide/endotoxin,
2. the peptidoglycan cell wall with peptide chains, par-
tially cross-linked, and
3. the cytoplasmic or inner membrane.
Gram-positive bacteria generally lack the outer mem-
brane. The main function of the outer membrane is to
serve as a permeability barrier, excluding certain drugs
and antibiotics from penetrating the cell [2]. This feature
is one of the main factors contributing to the intrinsic
antibiotic resistances observed in Gram-negative bacteria.
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• Enterobacteriaceae: Citrobacter spp., Enterobacter
spp., Escherichia coli,Klebsiella spp., Salmonella spp.,







Gram-negative bacteria can acquire resistance to one or
more important classes of antibiotics, which usually prove
effective against them such as:
1. Ureidopenicillins (piperacillin)
2. Third- or fourth-generation cephalosporins (cefo-
taxime, ceftazidime)
3. Carbapenems (imipenem, meropenem)
4. Fluorquinolones (ciprofloxacin)
5. Polymyxins (colistin and polymyxin B)
6. Aminoglycosides (gentamicin, amikacin)
7. Glycylcycline (tigecycline)




Definition of multidrug resistance varies between coun-
tries. In Germany, in the context of hospital hygiene, the
term multidrug-resistant organism (MDRO) is used for
Gram-negative bacteria which are resistant to three or
four out of the first four antibiotic groups listed above.
More specifically, 3MDRO (German: 3MRGN) means
multidrug-resistant Gram-negative organisms exhibiting
resistance to three out of the first four antibiotic groups
stated above, 4MDRO means resistance to all four
groups. It is important to note that the antibiotic groups
are not considered to be equally clinically relevant. Hence,
beta-lactamase resistant Enterobacteriaceae, which are
sensitive to fluorchinolones and carbapenems, are not
included herein [3].
An international panel of experts developed the following
definitions: Multidrug-resistant (MDR) means acquired
non-susceptibility to at least one agent in three or more
antimicrobial categories, extensively drug-resistant (XDR)
is defined as non-susceptibility to at least one agent in
all, but two or fewer antimicrobial categories, and
pandrug-resistant as non-susceptibility to all agents in
all available antimicrobial categories [4]. When comparing
and evaluating studies or guidelines and recommenda-
tions existing differences in definitions should be kept in
mind.
Among these acquired resistances, “The Big Five Car-
bapenemases” are of particular relevance. The “Big Five”
are:
1. KPC (Klebsiella pneumoniae carbapenemase)
2. IMP (Imipenemase metallo-beta-lactamase)
3. NDM (New Delhi metallo-beta-lactamase)
4. VIM (Verona integron-encoded metallo-beta-lacta-
mase)
5. OXA (Oxacillin carbapenemases)
Enterobacteriaceae, primarily Escherichia coli and Kleb-
siella pneumoniae, are among the most frequently af-
fected bacteria. Carbapenems are often the last line of
effective treatment available for infections with MDRO
Enterobacteriaceae.
Until recently, the polypeptide colistin has been used as
a reserve antibiotic for the treatment of critically ill pa-
tients in the event of multidrug resistance of GNB, espe-
cially in the event of resistance to carbapenem. However,
the emergence of the transferrable gene mcr-1, which
causes resistance to colistin, is now being reported from
several countries, including China, the U.K., Denmark,
the U.S. and Germany where it has been detected in in-
testinal bacteria in farm animals. Resistance to colistin
is particularly common in isolates of Escherichia coli and
in salmonella from poultry populations [5], [6]. In China,
the gene was found in humans, including residents of
long-term-care facilities, as well as in animals and food-
stuffs [7], [8], [9], [10].
Colistin belongs to the polymyxin group of antibiotics. It
binds to lipolysaccharides and phosopholipids in the
outer membrane of GNB. All resistance mechanisms
studied so far in this context eventually result in a reduced
affinity of polymyxin to the bacterial surface [11].
3 Acquisition and spread of
antibiotic resistance in
Gram-negative bacteria
Antibiotic resistance is essentially a result of natural se-
lection. Genetic variations in bacterial populations may
carry mutations, which prove to be advantageous for their
survival in the presence of antimicrobial agents.
Antibiotic resistance can be intrinsic to specific micro-
organisms, which can be explained by their inherent
structural or functional characteristics. Gram-negative
bacteria are usually naturally insensitive to vancomycin
because this antibiotic agent is not able to penetrate the
outer membrane.Klebsiella exhibit an innate insensitivity
towards ampicillin as a result of beta-lactamase produc-
tion. Pseudomonas aeruginosa is naturally insensitive,
e.g., to sulphonamides, tetracycline, chloramphenicol
and trimethoprim.
Apart from innate resistance, bacteria can acquire resist-
ance. Mutations in bacterial DNA can render antibiotics
ineffective, conveying a survival advantage to themutated
bacterial strain. This basically means, bacteria without
these advantages die or cannot reproduce in the presence
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of antibiotic agents, while resistant bacteria are able to
proliferate with less competition. Consequently, themore
antibiotics are used and disseminated, the greater the
likelihood that resistance strains will emerge.
Mutations in chromosomal genes can induce an increase
in the expression of intrinsic resistance mechanisms
(antibiotic-inactivating enzymes or efflux pumps) [12].
Resistance genes may also be acquired from other bac-
teria. They can be transferred between bacteria of the
same species but also of another species or genus.
Mechanisms of horizontal gene transfer include transduc-
tion, transformation and conjugation. Vectors carrying
one or more resistance genes may be plasmids (resist-
ance plasmid 1 is a common example in GNB), transpo-
sons (e.g. Tn5053) or integrons (e.g., Verona integron-
encoded metallo-beta-lactamase producing GNB). As for
GNB, in particular for Enterobacteriacea, there is evidence
suggesting that resistance genes and associated insertion
elements carried on plasmids are often found concen-
trated in large multiresistance regions (MRR) [13]. For
instance, ESBL- and carbapenemase-encoding plasmids
may carry resistance determinants for other antimicrobial
groups, including aminoglycosides and fluorquinolones
[12].
The possibility of a plasmid-mediated horizontal transmis-
sion of resistance genes between livestock and humans
(e.g. via the food chain) has been observed for ESBL-
genes and the colistin resistance gene mcr-1 in GNB [7],
[8], [14]. The inter-species transmission of multidrug-
resistant strains from humans to animals and vice versa
was also suggested following findings by a veterinary
diagnostic laboratory that the clonally related human B2-
O25:H4-ST131 CTX-M-15-type ESBL-producing E. coli
isolates is present in dogs and horses [15].
Yet another mechanism of emergence of antibiotic resist-
ance has been investigated for E. coli. Induction of a
mutagenic SOS-response by ciprofloxacin in E. coli caused
changes of their rod-like shape into multichromosome-
containing filaments. Bos et al. showed that initial resist-
ance emerged from successful segregation of mutant
chromosomes at the tips of filaments followed by budding
of resistant progeny. They proposed that the first stages
of emergence of resistance occur via the generation of
multiple chromosomes within the filament and are
achieved by mutation and possibly recombination
between the chromosomes [16].
An in-vitro experiment with chemostat cultures of
Pseudomonas aeruginosa by Feng et al. suggests that
the development of resistance during patient treatment
may be explained by a new acquisition of resistance
rather than by gene transfer. They conclude from their
studies that the risk of developing resistancemay possibly
be reduced by treating with antibiotics in the highest
concentration the patient can tolerate for the shortest
time needed to eliminate the infection [17].
One major factor believed to accelerate the spread of
antibiotic resistance is excessive use of antibiotic agents,
including also the use without treatment indication. The
emergence of resistance has occurred following the intro-
duction of each new class of antibiotics. A survey of van
Boeckel et al. on the total antibiotic sales in selected
countries from 2000 to 2010 reveals India to be the
country with the highest consumption (2010: nearly
13 billion standard units, standard unit means a single
dose unit, i.e. pill/capsule/or ampoule), followed by China
(approx. 10 billion standard units) and the U.S. (more
than 6 billion standard units, with a moderate decrease
from 2000 to 2010). Substantial increases in per capita
consumption of antibiotics were also reported from Aus-
tralia and New Zealand. Consumption of polymyxin in-
creased in each country apart from China [18].
Many studies have assumed that the broad spectrum of
antibiotics used in livestock do not only cause resistance
problems in pig populations, but also in public health
[19], [20], [21]. Multidrug-resistant bacteria with zoonotic
potential have developed in response to antibiotic use in
food animals [22]. In addition, a correlation between the
frequency of treatment and the occurrence of multidrug-
resistant bacteria in animals has been demonstrated.
The higher the treatment frequency (the average number
of days each animal in the herd is treated with antibiot-
ics), the higher the rate of resistance identified in isolates
from animal products [23]. Thus, the use of antibiotics
in both the health care system and in livestock production
may promote dissemination of resistance genes as a
direct consequence of selective pressure [24], [25], [26].
4 Surveillance and epidemiology
4.1 USA
In the U.S., the National Healthcare Safety Network
(NHSN) collects data on hospital-associated infections
(HAI). In their 2009–2010 report period (2,039 hospitals),
a slight decline in MRSA was observed, while an increas-
ing occurrence of multidrug-resistant Gram-negative
bacteria (E. coli, K. pneumonia, P. aeruginosa, A. bau-
manni, Enterobacter spp.) was reported. Although gener-
ally less common as a causative organism of HAIs, both
multidrug resistance and carbapenem resistance were
reported in more than 60% of Acinetobacter spp. among
most HAI types. 70%–80% of facilities reporting HAI with
Acinetobacter spp. reported at least onemultidrug-resist-
ant strain [27]. A 2010–2012 survey (Study for Monitor-
ing Antimicrobial Resistance Trends) on the resistance
rates of intra-abdominal isolates from U.S. intensive care
units and non-intensive care units revealed A. baumannii
isolates from ICU patients to be most likely to exhibit
resistance to more than four antibiotic classes [28]. The
most significant overall increase in carbapenem resist-
ance was observed for Klebsiella species (from 1.6% to
10.4%) in the NNIS/NHSN reporting [29].
As a consequence of this development, the Multi-Site
Gram-Negative Bacilli Surveillance Initiative (MuGSI) was
established as part of the Emerging Infections Program
of CDC in 2012. It conducts active population- and
laboratory-based surveillance in a defined surveillance
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catchment for six carbapenem-resistant organismswhich
include Escherichia coli, Enterobacter cloacae, Enterobac-
ter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca,
and Acinetobacter baumannii.
A report on “Antibiotic Resistance Threats in the United
States, 2013” was published by the Centers for Disease
Control and Prevention (CDC) [30]. The data show that
most antibiotic-resistant infections happen in the general
community, but most deaths related to antibiotic resist-
ance occur in healthcare settings. In this report, current
antibiotic resistance threats for each microorganism are
divided in three threat levels (urgent, serious, concerning).
For GNB (non-HAI included), the following categories ap-
ply:
• Carbapenem-resistant Enterobacteriaceae (CRE): Out
of 140,000 healthcare-associated Enterobacteriaceae
infections per year, more than 9,000 are caused by
CRE (urgent threat level)
• Neisseria gonorrhoea: Of 820,000 cases per year,
30% now demonstrate resistance to at least one anti-
biotic (urgent threat level)
• Multidrug-resistant Acinetobacter: Of 12,000 health-
care-associated Acinetobacter infections, 7,000 are
multidrug-resistant causing approx. 500 deaths per
year (serious threat level)
• ESBL-producing Enterobacteriaceae (ESBL-E): Of
140,000 Enterobacteriaceae infections per year,
26,000 are drug-resistant causing 1,700 deaths (ser-
ious threat level)
• Multidrug-resistant Pseudomonas aeruginosa: Of
51,000 Pseuodomonas infections per year, 6,700 are
multidrug-resistant causing 440 deaths (serious threat
level)
However, it should be noted that the most urgent threat
level pathogen in the U.S. is the Gram-positive bacterium
Clostridium difficile, causing 250,000 infections with
14,000 deaths per year. C. difficile associated deaths
are said to have increased by 400 % between 2000 and
2007 in the U.S. [30], [31]. C. difficile is also known to
have an inherent resistance to several antibiotics.
Moreover, a “hypervirulent” strain (NAP-1) has emerged
potentially producing more toxins than other strains and
exhibiting resistances to antibiotics such as vancomycin,
fidaxomicin, and metronizdazole [31], [32].
4.2 India
India with a population of 1.25 billion and a GNI/capita
of 5,350 USD compared to 44,540 and 53,960 respect-
ively for Germany and the U.S. has a completely different
healthcare structure and faces public health problems
like limited access to improved water and/or sanitation
and higher death rates from communicable diseases.
Administration of antibiotics is often a more feasible op-
tion than access to safe potable water and medical ad-
vice. The total expenditure on health in India per capita
is $109 compared to $6,471 in the U.S. Isolation facilities
are scarce, inadequate disposal of biomedical and gen-
eral waste and poor sanitation are examples for additional
problems, and screening for multidrug-resistant organ-
isms (MDRO) is not standard practice in most Indian
hospitals.
Reports from various studies from hospitals in India
suggest that the prevalence of ESBL-producing GNB range
between 19%and 60%, and that of carbapenem-resistant
GNB between 5.3% and 59% [33]. An alarming finding
from a molecular characterization study of carbapenem-
resistant Enterobacteriacea in Mumbai, West India, re-
vealed that 18.5% (21/113) of the clinical isolates inves-
tigated possessed dual carbapenemase genes [34].
Moreover, recently a series of 24 cases of colistin-resist-
antKlebsiella pneumoniae has been reported from a new
oncology center at Kolkata. The prevalence of ESBL- and
carbapenemase-producers in this area was estimated to
be 70% and 39%, respectively, resulting in a high first
line use of meropenem and colistin in this hospital [35].
In a study from South India, ESBL-production was detect-
ed in 53% of isolates from patients with community-ac-
quired bacteremia caused by E. coli and Klebsiella spp.
Among those isolates, the authors also found resistance
to multiple groups of antibiotics [36].
Antibiotic resistance has become a major public health
concern in India. However, as of today, a mandatory na-
tional surveillance system, uninform strategies and
quality control systems for sample selection andmethods
of susceptibility testing or mandatory antibiotic steward-
ship are lacking. A catalogue of strategies has been pro-
posed, including educational and awareness programmes
for community health services and the founding of an
“Alliance Against Antimicrobial Resistance” [37]. Two new
initiatives have been started in India in 2017. The first
one is the Indian Council of Medical Research (ICMR)
sponsored Antimicrobial Resistance SurveillanceNetwork
where several new Regional Centers have been estab-
lished in addition to the previously existing nodal centers.
Secondly, a CDC-ICMR and AIIMS (All India Institute of
Medical Sciences, NewDelhi) supported Capacity Building
project on AMR and Health Care Associated Infection
(HCAI) surveillance across the country were set up.
Hopefully these two new initiatives will enable better in-
fection control, better HCAI and antimicrobial resistance
surveillance along with strengthening infrastructure for
such activities across many regions of India (personal
communication).
4.3 Europe
Despite great variations within the 30 states reporting to
the EARS-Net (European Antimicrobial Resistance Surveil-
lance Network) in 2016, important resistance trends for
Gram-negative bacteria are recognizable [38]:
• Lower resistance levels reported in the northern and
western compared to the southern and eastern
European countries
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• Significant increase (from 2012 to 2015) of resist-
ances to third-generation cephalosporins in K. pneu-
moniae and E. coli, also in combination with ESBL
• Significant increase (from 2012 to 2015) of combined
resistance of third-generation cephalosporins with
fluoroquinolones and aminoglycosides for E. coli and
K. pneumoniae
• EU/EEA population-weighted mean for carbapenem
resistance 8.1% for K. pneumoniae, 0.1% for E. coli
(data referring to 2015)
• Wide inter-country variations for carbapenem resist-
ance in K. pneumoniae between 0 and 61.9%
• High percentages of combined resistance to fluorquino-
lones, third-generation cephalosporins and aminogly-
cosides often associatedwith reported high percentage
of carbapenem resistance (for K. pneumoniae)
• Significant increases for carbapenem resistance and
resistance to multiple antimicrobial groups also in
P. aeruginosa and Acinetobacter spp.
• Carbapenem resistance for E. coli remained stable
• Highest levels of resistance reported for Acinetobacter
spp. (with carbapenem resistance reaching over 80%
in some countries in the south and southeastern parts
of Europe and in the Baltic States)
• Isolates (e.g. of K. pneumoniae) with polymyxin resist-
ance were reported by some of the countries included
in EARS, showing that resistance to polymyxin is signi-
ficantly higher in carbapenem-resistant than in car-
bapenem-susceptible isolates.
The editors of the report point out that data on polymyxin
susceptibility from EARS-Net are to be interpreted with
caution due to variations in methodology and potential
selective testing. The joint CLSI-EUCAST Polymixin
Breakpoints Working Group has published a method to
determine colistin minimial inhibitory concentration dis-
tribution in 2016 [39].
As for C. difficile, a surveillance protocol was updated in
November 2015 to improve standardization of testing
and the quality of data reports [40]. It is estimated that
approximately 9% of all hospital-associated infections
are caused by C. difficile [40].
4.4 Germany
In Germany, the national surveillance system KISS (ab-
breviation for the German word for hospital infection
surveillance system) collects data of nosocomial infec-
tions from certain hospital risk areas (e.g., intensive care)
and high-risk patient groups (e.g., neonates). A KISS-
module for the surveillance of colonized or infected ICU
patients with selected MDRO, and of all hospitalized pa-
tients with MRSA and C. difficile associated diarrhea
(CDAD) in intensive care wards also exists. The German
Antimicrobial Resistance Surveillance System (ARS) is
cooperating partner of the European Antimicrobial Resist-
ance Surveillance Network (EARS-Net). In addition, a
surveillance database for antibiotic consumption for
hospitals has been established (AVS).
Evaluation of KISS data show that while MRSA remains
stable or is slightly decreasing, other MDROs among ICU
patients are becoming more common, and hospitalized
patients are twice as likely to acquire CDAD as they are
to acquire MRSA [41]. According to the point prevalence
study in 2011, which was carried out according to the
ECDC protocol, the most common pathogens found to
cause nosocomial infections in Germany were E. coli
(18%), Enterococci (E. faecalis and E. faecium, 13.2%),
S. aureus (13.1 %), and C. difficile (8.1%). The five most
commonly used classes of antibiotics were second-gen-
eration cephalosporins, followed by fluorquinolones,
penicillins with beta-lactamase inhibitors, third-generation
cephalosporins, and carbapenems. A substantial amount
of C. difficile infections was noted, thus confirming the
KISS data [42]. Maechler et al. report that the acquisition
rate of carbapenem-resistant organisms (CRO) in intensive
care units was more than double the rate of other MDRO
under surveillance by MDRO-KISS. CRO prevalence was
0.29 per 100 patients [43]. As a result of the increase in
carbapenem resistance, the German HealthMinistry has
released an ordinance for mandatory notification of
laboratory-confirmed colonizationwith carbapenem-resist-
ant organisms as of May 2016 [44].
Apart from data extracted from hospital surveillance
systems, the prevalence of antibiotic resistance in the
community is an important aspect for screening, infection
control and treatment regimens. In a study with
3,344 participants from southern Germany, 6.3% faecal
samples collected between October 2002 to November
2012were found to be positive for ESBL-producing E. coli
[45], suggesting that, in Germany, too, the community
has to be taken into consideration as a reservoir for anti-
biotic-resistant organisms and travelling abroad also
contributes to colonization with these bacteria.
4.5 Common trends
Although there are shortcomings in the report and surveil-
lance systems throughout the world and the reliability
and comparability of data is limited, there are many pat-
terns which are evident and which call for immediate
action. For example, carbapenem resistance is likely to
rise as a result of antibiotic resistance to other antibiotic
groups (such as 3rd generation cephalosporins) and an
increased use of reserve antibiotics. Similarly, colistin
resistance is thought to be associated with the rise in
CRO (carbapenem resistant organisms) and increased
usage of colistin as a reserve antibiotic.
Besides GNB, C. difficile infections, including those with
drug-resistant highly virulent strains, are on the rise and
need continuous monitoring. The acquisition and spread
of antibiotic resistance is a rapid, dynamic, global process
which is neither restricted to a specific bacterium, to
specific geographical areas or environments nor to hu-
mans or animals, nor to the healthcare system. On the
other hand, the fact that methicillin-resistant S. aureus
is actually receding or being contained in some places
shows that it is possible to reverse the trend by adequate
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policies such as systematic risk-adapted screening,
standard and contact infection control precautions and
antibiotic stewardship.
5 Methods for MDRO detection
Multidrug-resistant organisms (MDRO) may be detected
directly from clinical samples (e.g. stool, rectal, swab,
throat swab, wound swab, skin swab, etc.) by either cul-
ture-based phenotypic methods or PCR-based genotypic
methods. Culture-based methods are generally time
consuming (results taking 2–5 days), labour-intensive
and may suffer from problems of relatively low analytical
sensitivity. However, culture-basedmethods are relatively
inexpensive, may be performed in laboratories without
automation or advanced technology. Examples are the
modified Hodge test (MHT) and the Carba NP Test [46],
[47]. Genotypicmethods such asmultiplex and singleplex
PCR amplification and pulsed-field gel electrophoresis
(PFGE) are not widely available in hospital laboratories
around the world and are more expensive. PCR-based
methods provide more rapid results (within 1–2 days)
and have a high degree of analytical sensitivity because
of their ability to detect low numbers. However, unlike
culture-basedmethods, they are not able to give detailed
antibiotic susceptibility test results (except for the gene
of interest) andmay suffer from the problem of specificity
[48], [49], [50].
Examples for recent developments are the RAPIDEC®
CARBA NP assay for rapid detection of carbapenemases
in Enterobacteriacea, P. aeruginosa and Acinetobacter
spp., an immunochromatographic assay (the OXA-48 K-
SeT assay) to detect OXA-48-like carbapenemase-produc-
ing Enterobacteriaceae from culture colonies, as well as
a highly discriminatory universal blaSHV, blaTEM and
blaCTX-M subtyping assay of clinically important ESBL
genes, based on PCR and Sanger sequencing [51], [52],
[53], [54].
In addition, underestimation of the presence ofmultidrug-
resistant pathogensmay occur as GNB have the capacity
to survive in the viable-but-not-culturable state (VBNC-
state) as well as in biofilms, making detection by conven-
tional methods difficult [55]. For example, multidrug-re-
sistant A. baumannii has been shown to form biofilms on
the surfaces of respiratory epithelial surfaces and also
in the environment [56], [57].
As each bacterium and the respective resistance mech-
anism is associated with different epidemiological risks
and new mechanisms are being detected with new dia-
gnostic methods, it becomes apparent that a holistic and
proactive approach to tackle antibiotic resistance is im-
perative.
6 Habitats and reservoirs of
(antibiotic-resistant) Gram-negative
bacteria
6.1 Natural habitats and reservoirs
Natural habitats and reservoirs of GNB are, depending
on the species, soil, water, sewage, plants (fruit, vege-
tables, herbs), dairy products, raw meat as well as the
gastrointestinal tract of humans and animals, the skin
and the upper respiratory system (cf. Table 1).
6.2Reservoirs of Gram-negative bacteria
in healthcare facilities
Investigations of outbreaks with MDR Gram-negative
bacteria have revealed a number of reservoirs in hos-
pitals. These are, for example:
• Colonized/infected patients
• Biofilms, in humidifiers of incubators in neonatal wards
and other devices which are likely to form biofilms (cf.
[55] (Table 1); [58])
• Sinks/handwashing basins, faucets, drains, sink traps
[59]
• Standard toilets with a rim [60]
• Sewage/drainage system [61], [62], [63]
• All surfaces in hospitals such as beds/bedside sur-
faces, fabrics (linen, pillows, privacy curtains) [55],
[64]
• Computer keyboards and faucet handles [65]
• Duodenoscopes/endoscopes [66]
• Hospital foodstuff [67]
Most GNB thrive in a moist, humid environment. Con-
sequently, typical reservoirs include shower heads, bars
of soap, liquid soap, artificial fingernails, pools/hot
tubs/water fountains, dialysis tubing, infusion pumps,
respiratory equipment and cleaning mops. However, ac-
cording to a systematic review of the persistence of
nosocomial pathogens on inanimate surfaces, certain
Gram-negative species are also able to survive on inan-
imate, dry surfaces, even formonths. Prominent examples
are Acinetobacter spp., and Klebsiella spp. [68], [69]. On
the other hand, according to a recent study by Weber et
al. [70], carbapenemase-resistant Enterobacteriaceae
on various actively inoculated surfaces in CRE-patient
rooms showed less than 15% survival within 24 hours
and only infrequent (8.4%) and low levels of contamina-
tion (5.1 cfu/120 cm2). Further studies are necessary
before concluding from these findings that the risk of
CRE-transmission from environmental surfaces is rela-
tively low (cf. comment by A. Voss [71] on [68], [70]).
Outbreak investigations can contribute to the identifica-
tion of transmission paths within medical facilities. Apart
from direct person-to-person transmission involving (the
hands of) colonised or infected patients, visitors and staff,
transmission via all kinds of surfaces as well as aerosols,
both dust and droplets, must be taken into consideration.
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Table 1: Examples for frequent natural reservoirs and sites of colonization, transmission paths and types of infection of selected
Gram-negative bacteria
The sewage system and horizontal drainage systems as
reservoirs have proven to be associated with various
possibilities of transmission paths. One recently dis-
covered path were clogged pipes, which caused backwa-
ter, which can, in turn, contaminate sinks. When spirales
(drain snakes) were used to unclog drains and are
thereafter used in different areas of a hospital, the
pathogens can be transferred via the spirales [72].
Cleaning processes with aerosolization such as high
pressure cleaning with high-pressure water/steam bear
the risk of contaminating food or surfaces. All ecological
niches for Gram-negative bacteria such as sink drains,
traps and toilet brims can become a risk when surround-
ing surfaces (e.g. of counters used for preparing infusions)
or hands become contaminated by aerosol/droplet
formation. It is important to note that plasmids carrying
resistance genes can be transmitted across species
barriers as was the case in the multi-species outbreak
described above [72].
6.3Reservoirs of Gram-negative bacteria
in livestock
Livestock, especially pigs, cattle and poultry, as well as
pets and sheeps are a well-known reservoir for MDR-GNB
(e.g. [7], [15], [73], [74], [75], [76]). The primary focus
here is on ESBL-producing Enterobacteriaceae (ESBL-E).
Hot spots for transmission in the pig production chain
are the stable air as well as stressful crowding situations,
e.g. in humid, warm waiting areas before the abattoirs,
whereas carcasses in cold store do not constitute amajor
problem. While it has been clearly established that
farmers are at a higher risk of acquiring MRSA than the
general population – primarily as a result of transmission
by air/contaminated dust – the risk of colonization with
ESBL-E has not been fully elucidated [77]. However,
studies do exist suggesting that a direct transfer from
livestock to humans is possible [78].
Transmission of MDRO via food products and water is
also possible. Numerous publications have demonstrated
that drinking water, meat products ormilk can be contam-
inated with MDR-GNB and constitute a potential vehicle
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for pathogen transmission [7], [21], [79], [80], [81], [82],
[83].
Moreover, with the projected change in farming systems
inmiddle-income countries towards large-scale intensive
farming, routine use of antibiotics in subtherapeutic
doses, which are likely to accelerate resistance, is bound
to increase. According to van Boeckel et al., global con-
sumption of antimicrobials in livestock is estimated to
rise by 67% from 2010 to 2030 [84].
7Mortality from antibiotic-resistant
Gram-negative bacteria
Infections caused byMDR-GNB include urinary tract infec-
tions, blood stream infections (sepsis), pneumonia,
meningitis, diarrhea, gonorrhea, otitis, ocular infections
including endophthalmitis, device-related infections (e.g.
related to central vascular catheter placement) and
wound or intraabdominal infections.
Between October 2014 to May 2015, 40 carbapenem
resistant blood stream infections were observed in pa-
tients admitted to Tata Medical Center, Kolkata, India.
These were due to E. coli, K. pneumoniae, P. aeruginosa
and A. baumannii in 12, 15, 8 and 10 patients respect-
ively. The median age of the patients in this group was
48 years (range: 9.5 to 84.3 years). Twenty-one patients
had haematologic malignancy and 19 had solid organ
cancers. The 30-day all-cause mortality noted because
of these four multi-drug resistant bacteria (E. coli,
K. pneumoniae, P. aeruginosa and A. baumannii) was
0%, 40%, 50% and 60%, respectively. The median time
to mortality was 3 days after a positive blood culture with
carbapenem resistant Gram-negative bacteria (range
1–30 days). Stool surveillance cultures done in patients
admitted to the hospital during the same period showed
that 85% of the patients were colonised with one ormore
MDROs (n=156). Almost all E. coli and Klebsiella isolates
in stool were ESBL-producers. 20% of the E. coli and 45%
of Klebsiella isolates in stool were carbapenem-resistant.
Similarly, 36% of throat swab surveillance cultures
showed one ormoreMDROs (n=55). 40% of theKlebsiella
isolates from throat swabs were carbapenem-resistant
[85].
Data from WHO [86] confirm that the risk for bacterium-
attributable death from antibiotic resistant microorgan-
isms is significantly greater – twice that of patients with
non-resistant bacteria (e.g. this applies to E. coli which
are resistant to 3rd gen. cephalosporins, K. pneumoniae
with resistance to carbapenems). In their metaanalysis
of nine studies published up to April 2012 on mortality
following carbapenem-resistant Enterobacteriaceae in-
fections, the authors calculated that 26–44% of deaths
in 7 studies were attributable to carbapenem resistance
[87]. They compared all-cause deaths of patients with
carbapenem-resistant infections with those with car-
bapenem-susceptible infections. On the other hand, an
analysis of 24 studies for acquiring infections caused by
MDR-GNB in ICU published in 2016 cannot confirm a
direct association between infections due to Gram-
negative MDR bacteria and mortality in ICU patients,
which supports the need for further studies [88].
One of the main reasons for high mortality due to MDR-
GNB infection is a late onset of appropriate initial anti-
biotic therapy. Later administration of a suitable antibiotic
was found to be associated with an adverse outcome,
particularly in patients with a high-risk source such as
lungs, peritoneum or unknown origin of bacteraemia
caused by E. coli, K. pneumoniae, Enterobacter spp., and
P. aeruginosa. The adequately treated patient group had
a 27.4% mortality rate compared to 38.4% for the inad-
equately treated group. These findings are underlined by
observations that the median time from detection of the
positive blood culture to the time of death can be very
short (1–5 day for P. aeruginosa and 1–30 days for
Acinetobacter in the surveillance report from TataMedical
Center, India, see paragraph above [85]). Thus, for the
calculated antibiotic therapy, the immediate initiation of
treatment (within the first hour after diagnosis) is crucial
for the survival of the patient. In the first 6 hours, the
mortality risk of the antibiotic untreated septic shock was
reported to increase hourly by 7.6% [89].
In everyday practice, appropriate antibiotic therapy is not
always readily available on site, even if effective antibiot-
ics exist such as colistin for CR Klebsiella-induced pneu-
monia. In a study from Greece the vital role of combina-
tion therapy in the management of MDRO bacteraemia
was explored. It was found that out of the 205 patients
with blood stream infections caused by carbapenemase-
producingK. pneumoniae, the all-cause 28-daymortality
was 40%. A significantly higher mortality rate was ob-
served in patients treated withmonotherapy than in those
treated with combination therapy (44.4% versus 27.2%;
P=0.018). The lowestmortality rate (19.3%) was observed
in patients treated with carbapenem-containing combina-
tions. Combination therapy was strongly associated with
survival (HR of death for monotherapy versus combina-
tion, 2.08; 95% CI, 1.23 to 3.51; P=0.006), mostly due
to the effectiveness of the carbapenem-containing regi-
mens [90].
8 Risk factors for acquiring
infections caused by MDR-GNB
8.1 Hospital patients
The following risk factors associated with healthcare-as-
sociated infections caused by antimicrobial resistant
versus susceptible A. baumannii were identified for U.S.
hospitals [91]:
• Antibiotic use prior to infection
• Length of stay prior to infection
• Hospital A vs. B
• Respiratory infection
• Active duty in Iraq (“Iraqibacter of soldiers”) [92], [93]
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Similarly, in a systematic review of observational and ex-
perimental studies (published up to October 2015) with
regard to the prevalence of antibiotic resistance in urinary
tract infections caused by E. coli in children and young
people aged 0–17, the authors infer that children who
had previously received antibiotics in primary care were
more likely to exhibit resistance to antibiotics persisting
for up to six months after treatment [94].
Previous carriage of resistant organisms appears to be
another risk factor. In a case-control study including
276 CRE carriers in whom CRE carriage presumably
ended, following at least 2 negative screening samples
on separate days, Bart et al. found 36 (13%) to show re-
currencewithin one year after presumed eradication [95].
The recurrence rate was 25%when the carrier status was
presumed to have been eradicated 6 months after the
last known CRE-positive sample, compared with 7.5% if
presumed to be eradicated after 1 year. The authors
conclude that the CRE carrier status should bemaintained
for at least 1 year following the last positive sample and
they advise screening of all prior CRE carriers independent
of their current carriage status. Duration of carriage is
also extended in case of multiple hospitalization within
one year [96].
With regard to specific hospital wards, neonates and im-
munocompromised patients from intensive care units,
oncology and transplantation wards are at special risk.
A large number of studies confirm risk factors such as
recent organ or stem-cell transplantion, receipt of mech-
anical ventilation, extended hospital stay, previous
treatment with cephalosporins and carbapenems [97],
[98], [99]. Qureshi et al. recently reported 20 patients at
Pittsburgh Med Center known to be infected or colonized
with colistin-resistant A. baumannii. It was found mainly
among patients who had received colistin methansulfon-
ate (i.v. or inhaled) for treatment of carbapenem-resistant,
colistin-susceptibleA. baumannii infection (predominantly
ventilator-associated pneumonia) prior to identification
of colistin resistance. A 30-day all-cause mortality rate of
30% was recorded. Lipid A modification by the addition
of phosphoethanolamine was responsible for colistin
resistance [100].
In January of 2016, the German Robert Koch Institute
published a statement on the question of screening of
refugees and asylum seekers for MDRO which is kept
updated [101]. Few existing studies do suggest that the
proportion of asylum seeking people, including unaccom-
paniedminors, which are colonised with multidrug-resist-
ant ESBL-forming Gram-negative bacteria is significantly
higher than that of the general German population [101],
[102], [103]. The available national screening guidelines
have not been changed. They recommend to screen pa-
tients upon admission to hospital for MRSA and car-
bapenem-resistant organisms in case they are from re-
gions with a high prevalence of MDRO or in case they had
contact to the healthcare system outside of Germany or
if their clinical history is unclear. In the most recent study
published in Germany, 9.8% of the refugees were colon-
ized withMRSA, and 23.3%with resistant Gram-negative
bacteria [104]. Therefore, the authors recommend
screening and special infection control measures in
hospitals when refugees are admitted to hospitals, in or-
der to ensure best medical practice and safety for all
hospital patients regardless of their country of origin.
8.2 Nursing homes and long-term care
residents
Age >60 years is independently associated with MDR-
GNB [105]. New acquisition of MDR-GNB in nursing
homes and long-term care facilities within a relatively
short period of time is common in the United States and
may reach up to 50%, depending on the species [106],
[107]. Prevalence of MDR-GNB is now being reported to
exceed that of vancomycin-resistant Enterococci and
MRSA in the U.S. [108]. Molecular typing suggests that
person-to-person transmission within common areas in
LTCF (long-term-care facilities) is one important path of
transmission.
The following risk factors have been identified for various
MDR-GNB among residents in nursing homes and/or
long-term care facilities (cf. [107], [108], [109], [110],
[111], [112]): indwelling devices (urinary catheters and/or
feeding tubes), faecal incontinence, functional disability,
diabetes mellitus, previous antibiotic exposure, travelling
to high prevalence countries and antimicrobial use during
travels, advanced dementia. In a prospective cohort study
including 22 nursing homes in the greater Boston area
(U.S.A.), advanced dementia was associatedwith a spread
of MDR-GNB within a nursing home but also between
nursing homes. Genetically relatedMDR-GNB strainswere
detected in 18 of the 22 nursing homes. Residents with
advanced dementia should therefore be regarded as a
high-risk group.
8.3 Neurological rehabilitation clinics
and intensive in-home care
Neurological rehabilitation clinics also show high preval-
ence rates of MDRO, including GNB. Risk factors include
direct transfer from acute care hospitals, previous anti-
microbial treatment during the past 3months andwounds
[113].
Other non-acute settings outside the hospital which are
often neglected as risk factors include ambulatory care-
givers [113], intensive in-home care or structured residen-
tial services (group care settings) [114], [115].
8.4 Leisure and business travel, medical
tourism
According to a systematic assessment of 11 studies
(published up to August 2015) conducted by Hassing et
al., international travel is considered to be an important
risk factor for the carriage of multidrug-resistant En-
terobacteriaceae, with prevalences of >20% [116]. In
particular, the risk is increased for persons travelling to
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(southern) Asia and for persons with travel-related
diarrhea and antibiotic use. In the southeastern Asian
countries Thailand, Singapore,Malaysia, Vietnam, Indone-
sia, Philippines, Laos, Cambodia,Myanmar, Brunei 39.4%
of 436 isolates (E. coli, K. pneumoniae, K. oxytoca and
P. mirabilis) were positive for ESBL production. The pre-
valence of carbapenem-resistant (CR)A. baumannii varied
between 76 and 90%, of CR P. aeruginosa between 23
and 47% [117]. Similarly, Kuenzli et al. found high colon-
ization rates of ESBL-producing E. coli (ESBL-E) in Swiss
travellers to South Asia [118]. In a prospective cohort
study with 275 German volunteers travelling to 53 differ-
ent countries stool samples and travel-associated risk
factors such as type of travel, nutritional habits, occur-
rence of gastroenteritis were investigated before and
after the journey [119]. Pre-travel analysis demonstrated
a ESBL-E colonization rate of 6.8%. Thirty point four per-
cent of the previously uncolonized subjects were colonized
with ESBL-producing E. coli, and 8.6% were carriers of
ESBL-producing Klebsiella pneumoniae upon returning
to Germany, especially from those travelling to India and
to South East Asia. The authors recommend active sur-
veillance and contact isolation upon admission to
healthcare facilities for patients having travelled to India
and South East Asia in the previous 6 months [119].
Colonization of travellers with MDR-GNB appears to be
transient and disappears after 3–6 months [120].
Apart from holiday and business travel, medical tourism
and wellness tourism may be potential risk factors. Ac-
cording to the Medical Tourism Facts and Figures 2015
Report (International Medical Tourism) 6 million people
travel for medical treatment from one country to another
[121]. A comprehensive survey issued by OECD criticizes
the “grave lack of systematic data concerning health
services trade, both overall and at a disaggregated level
in terms of individual modes of delivery, and of specific
countries. This is both in terms of the trade itself, as well
as its implications”. The report explicitly mentions infec-
tion and cross-border spread of antimicrobial resistance
and dangerous pathogens as a risk associated with the
treatment processes [122].
Based on the important findings concerning risk assess-
ment of MDR-GNB described above, the subsequent
chapters will pinpoint important treatment and prevention
principles.
9 Principal treatment options
The current paradox is that while antibiotic resistance
and associated morbidity and mortality are increasing,
research for new antibiotics and novel mechanisms of
action has been decreasing. High costs for the develop-
ment and a poor return of investments are considered
to be the main reasons for this situation. Only a few new
agents are presently under clinical trial, among them the
non-β-lactam β-lactamase inhibitor avibactam and
plazomicin, a novel aminoglycoside [123], [124], [125].
9.1 Antibiotic stewardship
With respect to treatment options of infections caused
by MDR-GNB suitable and regionally adopted antibiotic
treatment regimens are to be laid down for each medical
facility and expert decisions have to be made for each
individual patient. For example, tigecycline and doripenem
have been successfully tried for treating infections caused
bymultidrug-resistant Acinetobacter spp. As a rule, using
the highest concentration of an antibiotic the patient can
tolerate for the shortest time needed to eliminate the in-
fection is recommended [126], [127], and combination
treatment may offer an advantage over monotherapy in
critically ill patients with severe infections caused by
carbapenemase-producing Klebsiella spp. [128]. On the
other hand, combination regimens are often associated
with more severe side effects [129].
9.2 Decolonization
Topical (skin) decolonization of MDR-GNB has proven
difficult or ineffective. A recent review of various decolon-
ization agents indicated that chlorhexidine gluconate and
sodium hypochlorite show the strongest evidence for
activity against Gram-negative organisms [130]. Use of
triclosan, hexachlorophene and povidone-iodine is not
recommended at this time.
Selective digestive and oropharyngeal decontamination
as a measure to prevent surgical site infection may have
a positive effect [131], but more studies are needed to
verify the benefits and to investigate a possible selection
for resistance among Gram-negative bacteria.
9.3 Antisepsis
Other novel treatment approaches such as the use of
antiseptics, probiotics, and bacteriophages are presently
being studied. The topical application of systemic antibi-
otics for skin, mucous membrane and wound infections
is obsolete with only one exception: The same antibiotic
is given orally or parenterally in case of metastatic infec-
tion [132], [133]. Antiseptics are more effective than
antibiotics in vitro [134], [135], equally effective in vivo
[136], [137] and, administered topically, as compatible
as antibiotic eye drops [138]. In contrast to antiseptics
with a microbiostatic specific mode of action (chlorhexid-
ine, triclosane, QAC, silver ions [cf. [138], [139], [140]]),
microbicidal antiseptics are without risk of development
of microbial resistance [141], [142], [143], [144].
10 Prevention strategies
10.1 Control of resistance emergence
and dissemination
In the 2014 draft of the Review on Antimicrobial Resist-
ance issued by the U.K. government [145] the authors
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begin with the optimistic statement on the chances to
bring the growing threat of antibiotic resistance under
control: “We believe that this crisis can be avoided. The
cost of taking action can be small if we take the right
steps soon. And the benefits will be large and long-lasting
especially for emerging economies […].” However, if anti-
microbial resistance is left untackled, they continue, an
estimated 10million deaths per year attributable to AMR
every year by 2050 will be the consequence. In the final
document published in 2016, O’Neill, chair of the review,
reflects “Indeed, even at the current rates, it is fair to
assume that over one million people will have died from
AMR since I started this Review in the summer of 2014.
This is truly shocking.” [146].
In order to prevent further spread, it is crucial to eliminate
sources for resistance development and reservoirs for
multidrug-resistant bacteria in the environment. Human,
agricultural, aqua farming, hospital and industrial waste
and waste water are a path for antimicrobials as well as
resistance genes and gene pools originating from a vast
bacterial spectrum via waste water treatment plants,
waste water and sludge/manure, thus contaminating
drinking water, surface water/groundwater and agricul-
tural soil. Standardized, reliable testing of environmental
samples must be employed to detect the contents of
resistant bacterial strains and antimicrobial residue/
agents in surface water, agricultural soil and drinking
water in order to adopt necessary control measures.
The extent to which certain sub-lethal concentrations of
antimicrobial agentsmay induce resistance and facilitate
horizontal gene transfer of resistance genes has not yet
been fully eludicated [147], [148].
One major prevention strategy is to curtail production,
prescription and consumption of antibiotics both in hu-
man and in veterinary medicine. Education of the general
population, of healthcare personnel, veterinarians and
pharmacists about means of prevention and proper
treatment of infections is also indispensable for this
process. Obligatory antibiotic stewardship programs in
human and in veterinary medicine, in dentistry as well as
in animal breeding should be enforced throughout the
world.
An equally important critical control point is the approach
to eliminate the need to employ antibiotics by offering
access to clean, affordable water and sanitation to all
people, by implementing infection control precautions in
medical facilities and everyday life, by promoting vaccin-
ation, and by introducing animal breeding and food-pro-
duction processes which render the use of antibiotics
unnecessary. Standardized surveillance and mandatory
notification of infections caused by multidrug-resistant
organisms supply crucial data for continual risk assess-
ment and risk management decisions.
A plethora of guidelines, recommendations and strategic
action plans, frameworks for action, including manuals
for developing national action plans with support tools
already exist on a national and international level, on the
prudent use of antibiotics, on combating emergence and
dissemination of antimicrobial resistance, on One Health
approaches to tackle antibiotic resistance, on antibiotic
use and resistance in food animals (cf. e.g. websites of
WHO, ECDC, CDC, CDDEP (Center for Disease Dynamics,
Economics & Policy), national public health services and
health ministries). Policy makers must be called upon to
ensure that these strategies are implemented and their
implementation is strictly adhered to.
10.2 Reservoir- and transmission-based
prevention strategies in healthcare and
long-term care facilities
Prevention strategies in healthcare include reservoir-
based and transmission-based measures. They may be
classified in different levels of evidence (e.g. strong and
conditional or classes I through IV, as in the U.K. and
German national recommendations, respectively [3],
[149]. Even though Gram-negative bacteria require spe-
cial attention, they are always part of a bundle of meas-
ures directed to all potential pathogens in a particular
environment.
The following strategies are generally recommended:
• Implementing a mandatory antibiotic stewardship re-
gimen
• Surveillance: Recording, reporting and evaluating
multidrug resistance
• Patient history and risk-based screening: Assessing
travel history (business, leisure, refugees), screening
of risk patients, contact precautions
• Assessing medical history/hospital stay within the
last 12months and screening of risk patients, contact
precautions
• Training and education of personnel responsible for
screening and contact precautions
• Principle of rapid diagnosis, quick transmission of in-
formation, quick treatment: Alert or flagging system
(flagging and electronic recording of MDRO carriers in
patient charts/patient database), appropriate informa-
tion of caregivers, patients, visitors and all hospital
personnel
• Monitoring and reinforcing infection control standard
precautions
• Additional contact precautions for patients known to
be or to have been colonized or infected with MDR-
GNB
• Safe decontamination practices and cleaning proto-
cols: e.g., avoiding aerosol formation (foam, sprays),
avoiding bacterial dissemination by inadequate disin-
fection techniques and materials, avoiding incorrect
dosage
• Antiseptic prevention and therapy of localized infec-
tions
• Discarding secretions/body fluids in designated areas
and cleaning sinks (not in hand wash sinks)
• Patient education: toilet use, emptying of urinary bags,
etc.
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• Safe disposal of (hospital) waste including safe
standard procedures for removing blockage/clogging.
Compliance is a major issue often discussed in this con-
text, including one special aspect: training and education
of patients and their families along with the staff may in-
crease compliance with and effectiveness of existing
guidelines. As a consequence, patients may be able to
participate in social and family-centred care programs
which would otherwise not be an option [150].
The followingmeasures are subject to debate and/or vary
according to availability of resources:
• Active screening: who, which microorganisms, how,
with which consequences?
• Antiseptic skin wash?
• Single room and/or cohort isolation [151], [152],
[153]?
• Environmental sampling: when, where and how?
• Monitoring disinfectant effectiveness: how often and
how?
10.2.1 Reservoir-based prevention
As mentioned earlier (Chapter 6), potential reservoirs for
MDR-GNB such as the plumbing system, sanitary facilities
as well asmedical instruments, e.g. complex endoscopes,
are often difficult to decontaminate. Therefore, it is an
interesting topic to consider modifications in technical
or/and architectural design:
• Hygienically intelligent/optimized sanitary facilities like
rimless toilets, appropriate sink and faucet design
(sloped angles to minimize splashing, offset drain,
sealed overflow, faucet spout for easy maintenance).
New self-disinfecting sink drains where shown to re-
duce the P. aeruginosa bioburden in a neonatal inten-
sive care unit [154].
• Optimized workflows and space for 2 beds per room
as a standard, sinks with appropriate design (see
above), sufficient space for personal belongings.
• No cabinets or storage areas beneath sinks.
• Point-of-use water filters in facilities for immunocom-
promised patients.
• Measures to prevent biofilm formation (adjustment of
water flow rate and water pressure).
• Materials/medical devices/surfaces which are easy
to clean and disinfect and which prevent biofilm
formation (e.g. specific (coated) materials for urinary
catheters).
• Maintaining a good quality of water supply in hospital
and community settings (for example through adequate
and appropriate levels of chlorination) and checking
the water quality microbiologically by sensitive tech-
niques [155].
10.2.2 Example for transmission-based
prevention strategies: Disinfection of surfaces
Effective disinfection is one of the most important parts
of the multi-barrier approach to prevent dissemination of
MDR-GNB [156], [157]. This is not only applicable to
areas of medical care of humans, but also to veterinary
medicine and, for example, to livestock breeding.
Schmidthausen et al. demonstrated that a comprehensive
cleaning and disinfection regimen as part of an interven-
tion bundle in the stables of a pig farmwas able to effect-
ively eradicate MRSA and β-lactamase producing En-
terobacteriaceae [158].
Frequently used biocides contain quaternary ammonium
compounds, alcohols, aldehydes, peroxides, chlorine
compounds, amphoteric substances. In a comparative
evaluation of the efficacy of surface disinfectant cleaners
composed of different active agents against multidrug-
resistant clinical isolates of GNB, Reichel et al. confirmed
that the tested surface disinfectants exhibited sufficient
efficacy when tested according to the method described
in the standard EN 13727:2012 under dirty conditions.
However, in their conclusion the authors do state that
individual clinical isolates (e.g. one 4MRGN P. aeruginosa
isolate) might exhibit reduced susceptibility to selected
biocidal agents (e.g. aldehyde-containing surface-active
substances) [159].
Also, quaternary ammoniumcompounds have been found
to be less effective against S. marcescens than other
active agents: Investigations to clarify an outbreak with
S. marcescens in a German hospital showed that disin-
fectionwith a product containing 3 quaternary ammonium
compoundswas ineffective againstS.marcescens clinical
isolates which were detected on the lid and the bottom
of a disinfectant wipe container. The removal of the first
wipe with the lid open was thought to have caused con-
tamination. When products containing peroxides were
used, disinfection was successful (paper presented by
Goroncy-Bermes at the RSS SymposiumNovember 2015
[160]). Recent research has indicated that bacterial genes
(qac genes)may encode efflux pumps capable of expelling
quaternary ammonium compound structures from bac-
terial cells (MRSA), rendering these compounds less ef-
fective [161]. A high prevalence of qacE resistance genes
was found among clinical isolates of MDR Acinetobacter
baumannii in a Malaysian tertiary care hospital [162].
Silveira et al. report a hospital sewage ST17 Enterococcus
faecium with a transferable Inc18-like plasmid carrying
genes for resistance to antibiotics and to quaternary
ammonium compounds [163].
Still, as regards the correlation between non-susceptibility
to surface disinfectants and to antibiotics, research so
far suggests that in general there is no risk of selection
for antibiotic resistance provided disinfectants are used
in the correct dosage [164], [165], except for Triclosan
and quaternary ammonium compounds (QAC) which are
among the active agents suspected to trigger resistance,
especially when used in sublethal doses (cf. [166], [167],
[168]).
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These findings show that continuous research and devel-
opment in disinfection is essential. Legal challenges such
as the Biocidal Products Regulations, which will lead to
a reduction in the active agents available for disinfection
in the medical field, complex approval processes for
marketing biocides and incurring costs impede invest-
ments in innovative research by industry. Rather than
taking risk/benefit assessment as the basis for classifi-
cation of substances, the hazard of a substance is evalu-
ated independent from its route of exposure and its health
benefits. User acceptance of effective substances with
a long list of hazard labels will be low and substances for
targeted, niche application for professional use will be-
come scarce. Thus, there is growing concern that the
availability of effective biocides in future cannot be en-
sured (paper presented by Oltmanns at the RSS symposi-
um November 2015 [169]).
Apart from the availability of suitable active agents,
training and education of cleaning staff, disinfection
protocols which are easy to implement and disinfection
techniques which are easy to perform are an essential
contribution to safe and effective disinfection.
10.2.3 Prevention strategies in agriculture:
Example of pig stables in Germany
Experimental studies on the decontamination of pig
stables [170] were based on knowledge that hygiene and
sanitationmeasures are a compelling necessity to combat
endemic hospitalism (autochthonous risk) in modern
livestock production [171], [172], [173]. This means
preventing and inhibiting the spread of facultative
pathogenic bacteria that occur in animal husbandry and
in hospitals and healthcare systems (hospitalism germs)
[173]. In this context there is an increasing demand for
the further development of new concepts and procedures
to control or even eradicate drug-resistant bacteria and,
thus, interrupt infection chains. Single treatment of anim-
als for purposes of decolonization or therapy, similar to
practices in human medicine, requires too much effort
and fails entirely if high numbers of animals are affected
within a large herd [173], [174], [175]. Moreover, not
only do animals present potential reservoirs or vectors
for transferring resistance genes and resistant bacteria,
but farmers and farm workers, the stable environment
including surfaces, installations, and many more factors
should also be considered for their transmission potential
[176], [177], [178]. Generally, farmmanagement systems
should include specific hygiene and sanitationmeasures
to interrupt infection chains [173], [179], [180]. The
twelvemeasures of prophylaxis and therapy ofMayr [181]
coincide, to a large extent.
Sanitation of the stable environment
Although all of the recommendations given below are
based on the infrastructure and regulations in Germany,
they may give some ideas and trigger developments for
sanitation measures in agriculture in other countries.
• Construct a closed-off quarantine stable and sick
stable in which potentially introduced diseases can be
controlled or treated in order to prevent an outbreak
[173], [182], [183].
• Uninstall all technical installations and supply lines,
including water/feed and ventilation systems [179],
[180].
• Remove damaged floors, separations, and all materials
(wood, etc.) that could provide potential reservoirs for
pathogens and replace with easily cleanable and
smooth materials [174].
• Exchange technical equipment (driving boards, etc.)
within individual stables and compartments [184].
• Disinfestmanure according to stipulations of the waste
removal law [173], [185].
Elimination and reduction of pathogenic bacteria
• Clean using a high-pressure cleaner and water.
• Foam and repeat cleansing with water.
• Dry all objects and surfaces to be disinfected [173].
• Apply disinfecting agents with bactericidal, virucidal,
fungicidal, and antiparasitic properties to all surfaces,
in wet form, in sufficient concentration [186] and
nebulize hot steam onto all hard-to-reach spots (for
example, main ventilation shafts, etc.). This final disin-
fection serves to eliminate MRSA and ESBL E. coli, as
well as other bacterial groups [187].
• Allow sufficient drying time and “stable rest” before
resuming stabling of any animal [173].
Enhancement of the individual defense mechanisms
and control of the resistance status
• Limit the purchase of new pigs to those that are accom-
panied with health certificates from the supply farms
[181].
• Specifically vaccinate with a focus on the viral respir-
atory diseases that have a high prevalence in the ap-
plicable region [181].
• Certification of a negative MRSA and ESBL E. coli
status by appropriate monitoring [188].
It has to be emphasized that combating antibiotic resist-
ance has to based on a multi-faceted approach compris-
ing the developed and the developing world. Prevention
of the spread of antibiotic resistance “from farm to fork”
is one essential constituent in the One Health approach
[189].
11 A look into the future
It is undisputed that collaborative efforts such as the
“World Alliance Against Antibiotic Resistance”, and the
“Joint Programming Initiative on Antimicrobial Resist-
ance”, among others, are needed to tackle the hazards
posed by antibiotic resistance [190].
For example, novel approaches in pharmaceutical re-
search such as overcoming the intrinsic resistance of
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GNB by designing glycopeptide analogues which can
permeate the outer membrane of GNB can lead to inter-
esting therapeutic options, which may help counteract
the impact antibiotic resistance has on the therapy op-
tions of immunosuppressed patients [191].
In addition, there is need for alternative approaches fo-
cussing on infection prevention, which make the use of
antimicrobial agents unnecessary. Novel designs for
equipment and fittings which serve as a reservoir for GNB,
are of special interest. These include plumbing systems,
sinks and sink drains, water outlets, medical devices as
well as washing machines (cf. [55]).
“At the present time, our best defense against (MDRO)
… remains old-fashioned, stringent infection control
measures combined with the application of effective an-
timicrobial stewardship” [192]. Although this sentence
sounds like an easy “take homemessage” it does implic-
ate that infection control measures are only as good as
they are implemented stringently and concomitantly with
antimicrobial stewardship, which is difficult but not im-
possible to achieve. Thus, for example, endemic MDR
A. baumannii in ICUs of Chungnam National University
Hospital in Daejeon, South Korea, was brought under
control by introducing an enforcing antimicrobial steward-
ship along with comprehensive, intensified infection
control measures, including cohorting of patients in de-
signated areas and promotion and monitoring of hand
hygiene and environmental cleaning and disinfection
protocols [193].
It has also been shown that Organizational Culture (staff
engagement) is positively correlated with prevention atti-
tudes and compliance with contact precaution protocols
and negatively correlated with carbapenem-resistant
Enterobacteriaceae acquisition rates [194]. The principle
of “Patient Safety First” should be laid down in quality
assurance regulations and include preventing antibiotic
resistance and handling of MDRO, respectively, but it
must also be part of a culture of patient safety. It cannot
be overemphasized that awareness, rules and regulations
will not automatically result in a change in routines nor
in skilled and effective performance of the necessary
chores.
Again, theses measures do not specifically target GNB.
However, as we search for strategies, it becomes appar-
ent that detailed investigations on Gram-negative bac-
teria, their intrinsic resistance, the spread of acquired
resistance, the difficulties in reliable and rapid diagnosis,
their ubiquitous reservoirs have forced all those involved
with the prevention of infection to develop a “global per-
spective” and a “One Health perspective” which will
eventually benefit all efforts to curtail antibiotic resist-
ance.
Meanwhile – shortly before publication of this paper –
WHO has published a Global priority list of antibiotic-res-
istant bacteria to guide research, discovery, and develop-
ment of new antibiotics [195]. It addresses the urgent
need for research efforts for GNB-MDR as they pose a
particular threat to hospitals, nursing homes and patients
requiring ventilation and catheterization. They are to be
considered the most critical group of multidrug-resistant
bacteria.
12 Conclusions
In view of these developments, the authors have agreed
on the following principle key points to be addressed to
various target groups where applicable:
Policy makers
• Issue guidelines
• Support efforts in research and development (see be-
low)
• Establish legal framework for mandatory implementa-
tion of guidelines
• Take care of water and sanitation and waste manage-
ment
• Support education and training for the general public
• Support adequate education and training for medical
students and personnel
General public
Increase knowledge about infection prevention and
prudent use of antibiotics
•
Resident physicians/dentists
Comply with antibiotic stewardship•
Substitute antibiotics by analogous or even higher
effective measures, i.e. antiseptics, probiotics, and
bacteriophages
•
Hospital and medical facilities
Create a patient safety culture•
Implement prevention and infection control precau-
tions
•
Implement novel strategies for building sink/sink
drainage and sewage systems
•
Implement adequate design of patient rooms and
wards
•
Healthcare professionals and caregivers
Comply with rules and regulations•
Promote patient empowerment•
Take advantage of training and education•
Infection control preventionists
Devise guidelines and recommendations•
Identify research gaps•
Monitor implementation of guidelines•
Industry
• Research & development (pharmaceuticals, medical
devices, architectural, disinfectants, fittings and fur-
nishings)
Agriculture
Reduce antibiotic use in farming/animal breeding•
Implement sanitation of stable environment•
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Eliminate and reduce pathogenic bacteria by
cleaning and disinfection
•
Enhance individual defense mechanisms and
monitoring of resistance status
•
Research & development
• Develop new antibiotics against MDRO-GNB
• Develop safer and more effective biocides against
MDRO-GNB
• Providemeans for rapid diagnosis of sepsis andMDRO-
GNB-associated sepsis
• Explore role of specific dietary and nutritional interven-
tions in reducing/ suppressing gut colonization by
MDR-GNBs
Role of bael fruit/yoghurt (curd)•
Micronutrients: Vitamins/minerals•







• Explore feasibility of vaccines against certain MDR-
GNB (e.g. against Klebsiella)
• Explore role of pre-operative or pre-intervention (e.g.
transplantation) screening for MDR-GNB in reducing
post-intervention infective morbidity and mortality
• Develop new strategies in the design and infrastructure
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